Roivant Sciences Ltd.

Last updated September 27, 2026

Organization details

Legal name
Roivant Sciences Ltd.
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Bermuda
Headquarters city
London
Headquarters country
United Kingdom
Fiscal year end
March
Ticker symbol
ROIV
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001635088
EIN
98-1173944

Board of directors

Chief executives

Matthew Gline · CEO
Dates unknown

Director election results

Annual meeting of September 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

6 of this board's directors also sit on 5 other boards. 3 are in the same sector.

Network of Roivant Sciences Ltd.'s board connections Arbutus Biopharma Corporation Arbutus Biopharma Corp... BridgeBio Pharma Inc. BridgeBio Pharma Inc. Nautilus Biotechnology Inc. Nautilus Biotechnology... Okeanis Eco Tankers Corp. Okeanis Eco Tankers Co... Tenet Healthcare Corporation Tenet Healthcare Corpo... Daniel Allen Gold Daniel Allen Gold James C. Momtazee James C. Momtazee Keith S. Manchester Keith S. Manchester Matthew Gline Matthew Gline Meghan Fitzgerald Meghan Fitzgerald Melissa B. Epperly Melissa B. Epperly Roivant Sciences Ltd.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$895,243,129
117 sales by 12 insiders
Date Insider Transaction Shares Price Value
Nov 3, 2026 Eric Venker Officer (President & Immunovant CEO) Open-market sale −200,000 $36.31 $7,262,000
Oct 28, 2026 Eric Venker Officer (President & Immunovant CEO) Open-market sale −200,000 $36.59 $7,318,000
Oct 23, 2026 Melissa B. Epperly Director Grant or award +513 — —
Oct 23, 2026 James C. Momtazee Director Grant or award +383 — —
Oct 23, 2026 Ilan Oren Director Grant or award +810 — —
Oct 23, 2026 Melissa B. Epperly Director Shares withheld for tax −116 $36.49 $4,233
Oct 23, 2026 James C. Momtazee Director Shares withheld for tax −77 $36.49 $2,810
Oct 20, 2026 Eric Venker Officer (President & Immunovant CEO) Open-market sale −185,856 $35.09 $6,521,687
Oct 20, 2026 Eric Venker Officer (President & Immunovant CEO) Open-market sale −14,144 $35.42 $500,980
Oct 16, 2026 Matthew Gline Director, Officer (CEO) Shares withheld for tax −34,638 $33.53 $1,161,412
Oct 16, 2026 Mayukh Sukhatme Director, Officer (President & CIO) Shares withheld for tax −19,976 $33.53 $669,795
Oct 1, 2026 Melissa B. Epperly Director Option exercise +17,750 $4.46 $79,165
Oct 1, 2026 Melissa B. Epperly Director Open-market sale −16,850 $36.08 $607,948
Oct 1, 2026 Melissa B. Epperly Director Open-market sale −900 $36.57 $32,913
Sep 30, 2026 Matthew Gline Director, Officer (CEO) Shares withheld for tax −76,171 $36.57 $2,785,573

Organizations in the same sector, closest in location and size first.

Questions about Roivant Sciences Ltd.

Who is the CEO of Roivant Sciences Ltd.?

Matthew Gline is Roivant Sciences Ltd.'s CEO.

How many directors are on Roivant Sciences Ltd.'s board?

Roivant Sciences Ltd.'s board has 9 directors: Daniel Allen Gold, Ilan Oren, James C. Momtazee, Keith S. Manchester, Matthew Gline, Mayukh Sukhatme, Meghan Fitzgerald, Melissa B. Epperly and Vivek Ramaswamy.

Are Roivant Sciences Ltd. insiders buying or selling shares?

Over the last 12 months, Roivant Sciences Ltd. insiders made no open-market purchases and sold $895.2 million of shares in 117 sales on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="roivant-sciences-ltd"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.